Skip to main content Accessibility help
×
Home
  • Print publication year: 2007
  • Online publication date: January 2010

7 - Immune responses to tumours: current concepts and applications

Related content

Powered by UNSILO
References
Jager, D, Jager, E, Knuth, A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001; 54: 669–74.
Boshoff, C, Weiss, R. AIDS-related malignancies. Nat Rev Cancer 2002; 2: 373–82.
Jaffe, ES, International Agency for Research on Cancer. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, Lyon, 2001).
Venitt, S. Mechanisms of spontaneous human cancers. Environ Health Perspect 1996; 104 (Suppl 3): 633–7.
Roitt, IM, Delves, PJ. Roitt's Essential Immunology (Blackwell Science, Malden, MA, 2001).
Goldsby, RA. Immunology (Freeman, New York, 2003).
Parham, P. The Immune System (Garland Publishing, New York, 2000).
Soilleux, EJ. DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) and DC-SIGN-related (DC-SIGNR): friend or foe?Clin Sci (Lond) 2003; 104: 437–46.
Hart, DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245–87.
Cotran, RS, Kumar, V, Collins, T, Robbins, SL. Robbins Pathologic Basis of Disease (Saunders, Philadelphia, 1999).
Coventry, BJ, Austyn, JM, Chryssidis, S, Hankins, D, Harris, A. Identification and isolation of CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. Adv Exp Med Biol 1997; 417: 571–7.
Gilliet, M, Liu, YJ. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 2002; 63: 1149–55.
Knight, SC, Askonas, BA, Macatonia, SE. Dendritic cells as targets for cytotoxic T lymphocytes. Adv Exp Med Biol 1997; 417: 389–94.
Cooper, MA, Fehniger, TA, Caligiuri, MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633–40.
Takanami, I, Takeuchi, K, Gika, M. Immunohistochemical detection of eosinophilic infiltration in pulmonary adenocarcinoma. Anticancer Res 2002; 22: 2391–6.
Hung, K, Hayashi, R, Lafond-Walker, Aet al. The central role of CD4(+) T-cells in the antitumor immune response. J Exp Med 1998; 188: 2357–68.
Ancuta, P, Weiss, L, Haeffner-Cavaillon, N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol 2000; 30: 1872–83.
Linehan, SA, Martinez-Pomares, L, Stahl, PD, Gordon, S. Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: in situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med 1999; 189: 1961–72.
Kawakami, T, Galli, SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002; 2: 773–86.
Hermes, B, Feldmann-Boddeker, I, Welker, Pet al. Altered expression of mast cell chymase and tryptase and of c-Kit in human cutaneous scar tissue. J Invest Dermatol 2000; 114: 51–5.
Dimitriadou, V, Koutsilieris, M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis?Anticancer Res 1997; 17: 1541–9.
Matzinger, P. The danger model: a renewed sense of self. Science 2002; 296: 301–5.
Figdor, CG, Kooyk, Y, Adema, GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2002; 2: 77–84.
Nguyen, LT, Elford, AR, Murakami, Ket al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002; 195: 423–35.
Janeway, CA Jr.The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13: 11–16.
Kirschning, CJ, Schumann, RR. TLR2: cellular sensor for microbial and endogenous molecular pattrns. Curr Top Microbiol Immunol 2002; 270: 121–44.
Termeer, Cet al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195: 99–111.
Basu, S, Binder, RJ, Suto, R, Anderson, KM, Srivastava, PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12: 1539–46.
Fuchs, EJ, Matzinger, P. Is cancer dangerous to the immune system?Semin Immunol 1996; 8: 271–80.
Sahin, U, Tureci, O, Schmitt, Het al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810–13.
Rosenberg, SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001; 250: 462–75.
Yee, C, Greenberg, P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2002; 2: 409–19.
Kiessling, A, Schmitz, M, Stevanovic, Set al. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002; 102: 390–7.
Nelson, PS. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles. Ann NY Acad Sci 2002; 975: 232–46.
Bonner, PL, Lill, JR, Hill, S, Creaser, CS, Rees, RC. Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. J Immunol Methods 2002; 262: 5–19.
Preuss, KD, Zwick, C, Bormann, C, Neumann, F, Pfreundschuh, M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002; 188: 43–50.
Mazzocchi, A, Storkus, WJ, Traversari, Cet al. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J Immunol 1996; 157: 3030–8.
Ruffini, PA, Neelapu, SS, Kwak, LW, Biragyn, A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 2002; 87: 989–1001.
Blanke, CD, Eisenberg, BL, Heinrich, MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001; 2: 485–91.
Eisenbach, L, Bar-Haim, E, El-Shami, K. Antitumor vaccination using peptide based vaccines. Immunol Lett 2000; 74: 27–34.
Rickinson, AB. Immune intervention against virus-associated human cancers. Ann Oncol 1995; 6(Suppl 1): 69–71.
Imahayashi, S, Ichiyoshi, Y, Yoshino, Iet al. Tumor-infiltrating B-cell-derived IgG recognizes tumor components in human lung cancer. Cancer Invest 2000; 18: 530–6.
Coronella, JAet al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 2001; 61: 7889–99.
O'Brien, PM, Tsirimonaki, E, Coomber, DWet al. Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection. Cancer Immunol Immunother 2001; 50: 523–32.
Petty, JK, He, K, Corless, CL, Vetto, JT, Weinberg, AD. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 2002; 183: 512–18.
Kuo, SH, Chang, DB, Lee, YC, Lee, YT, Luh, KT. Tumour-infiltrating lymphocytes in non-small cell lung cancer are activated T lymphocytes. Respirology 1998; 3: 55–9.
Gaffey, MJ, Frierson, HF Jr, Mills, SEet al. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance. Mod Pathol 1993; 6: 721–8.
Yannelli, JRet al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 1996; 65: 413–21.
Suekane, S, Nakao, M, Inoue, M, Noda, S, Itoh, K. Histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of patient with testicular embryonal cancer. Jpn J Cancer Res 1997; 88: 1181–9.
Dadmarz, RD, Ordoubadi, A, Mixon, Aet al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC Class II-restricted fashion. Cancer J Sci Am 1996; 2: 263.
Boon, T, Cerottini, JC, Eynde, B, Bruggen, P, Pel, A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337–65.
Topalian, SL, Rivoltini, L, Mancini, Met al. Human CD4+ T-cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91: 9461–5.
Hasenkrug, KJ, Brooks, DM, Dittmer, U. Critical role for CD4(+) T-cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 1998; 72: 6559–64.
Dunn, GP, Bruce, AT, Ikeda, H, Old, LJ, Schreiber, RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991–8.
Hohn, H, Pilch, H, Gunzel, Set al. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol 1999; 163: 5715–22.
Street, SE, Trapani, JA, MacGregor, D, Smyth, MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129–34.
Zeng, G. MHC Class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. J Immunother 2001; 24: 195–204.
Khong, HT, Restifo, NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 2002; 3: 999–1005.
Dionne, SO, Smith, MH, Marincola, FM, Lake, DF, Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes. Cell Immunol 2001; 214: 139–44.
Kooi, S, Zhang, HZ, Patenia, Ret al. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996; 174: 116–28.
Kuge, Set al. Interleukin-12 augments the generation of autologous tumor-reactive CD8+ cytotoxic T lymphocytes from tumor-infiltrating lymphocytes. Jpn J Cancer Res 1995; 86: 135–9.
Shimizu, Y, Weidmann, E, Iwatsuki, S, Herberman, RB, Whiteside, TL. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res 1991; 51: 6153–62.
Enomoto, A, Kato, K, Yagita, H, Okumura, K. Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice. Cancer Immunol Immunother 1997; 44: 204–10.
Kohda, H, Sekiya, C, Torimoto, Yet al. Importance of cytotoxic T lymphocytes in the rejection of transplanted hepatocellular carcinoma. J Gastroenterol 1994; 29: 282–8.
Rees, RC, Mian, S. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother 1999; 48: 374–81.
Ferrarini, M, Ferrero, E, Dagna, L, Poggi, A, Zocchi, MR. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23: 14–18.
Schiltz, PM, Beutel, LD, Nayak, SK, Dillman, RO. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother 1997; 20: 377–86.
Lee, RS, Schlumberger, M, Caillou, Bet al. Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours. Eur J Cancer 1996; 32A: 1233–9.
Hald, J, Rasmussen, N, Claesson, MH. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother 1995; 41: 243–50.
Hilders, CG, Ras, L, Eendenburg, JD, Nooyen, Y, Fleuren, GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994; 57: 805–13.
Nakashima, M, Janiszewska, M, Steplewski, Zet al. Proliferation, phenotype, and cytotoxicity of human lymphocytes isolated from lymph nodes invaded by melanoma cells. Hybridoma 1994; 13: 241–6.
Karimine, N, Nanbara, S, Arinaga, Set al. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. J Surg Oncol 1994; 55: 179–85.
Ostenstad, B, Lea, T, Schlichting, E, Harboe, M. Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area. Gut 1994; 35: 382–7.
Hayakawa, K, Salmeron, MA, Parkinson, DRet al. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T-cells in RCC. J Immunother 1991; 10: 313–25.
Ljunggren, HG, Ohlen, C, Hoglund, Pet al. Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts. J Immunol 1998; 140: 671–8.
Mather, GG, Talcott, PA, Exon, JH. Characterization of a chemically induced tumor model and the effects of natural killer cell depletion by antiasialo GM-1. Immunobiology 1994; 190: 333–45.
Kusmartsev, S, Gabrilovich, DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 51: 293–8.
Zou, W, Machelon, V, Coulomb-L'Hermin, Aet al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339–46.
Salio, M, Cella, M, Vermi, Wet al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33: 1052–62.
Clark, WH Jr, Elder, , Guerry, D 4thet al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893–904.
Clemente, CG, Mihm, MC Jr, Bufalino, Ret al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303–10.
Menard, S, Tomasic, G, Casalini, Pet al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997; 3: 817–19.
Branston, LK, Greening, S, Newcombe, RGet al. The implementation of guidelines and computerised forms improves the completeness of cancer pathology reporting. The CROPS project: a randomised controlled trial in pathology. Eur J Cancer 2002; 38: 764–72.
Halliday, GM, Patel, A, Hunt, MJ, Tefany, FJ, Barnetson, RS. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T-cells. World J Surg 1995; 19: 352–8.
Patel, A, Halliday, GM, Cooke, BE, Barnetson, RS. Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma. Br J Dermatol 1994; 131: 789–98.
Furihata, M, Ohtsuki, Y, Sonobe, Het al. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku J Exp Med 1993; 169: 187–95.
Ishigami, S, Natsugoe, S, Tokuda, Ket al. CD3-zetachain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 2002; 94: 1437–42.
Funada, Y, Noguchi, T, Kikuchi, Ret al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003; 10: 309–13.
Epstein, NA, Fatti, LP. Prostatic carcinoma: some morphological features affecting prognosis. Cancer 1976; 37: 2455–65.
Vesalainen, S, Lipponen, P, Talja, M, Syrjanen, K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30A, 1797–803.
Bansberg, SF, Olsen, KD, Gaffey, TA. Lymphoepithelioma of the oropharynx. Otolaryngol Head Neck Surg 1989; 100: 303–7.
Ahuja, AT, Teo, PM, To, KF, King, AD, Metreweli, C. Palatal lymphoepitheliomas and a review of head and neck lymphoepitheliomas. Clin Radiol 1999; 54: 289–93.
Bernstorff, W, Voss, M, Freichel, S. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001; 7: 925s–32s.
Mihm MC, , Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 43–7.
Finn, OJ, Forni, G. Prophylactic cancer vaccines. Curr Opin Immunol 2002; 14: 172–7.
Koutsky, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–51.
Schuler, G, Schuler-Thurner, B, Steinman, RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138–47.
Pardoll, DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227–38.
Paul, S, Calmels, B, Acres, RB. Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. Curr Gene Ther 2002; 2: 91–100.
Yu, Z, Restifo, NP. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002; 110: 289–94.
Schamhart, DH, Boer, EC, Reijke, TM, Kurth, K. Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol 2000; 37(Suppl 3): 16–23.
Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118–29.
Turk, MJ, Wolchok, JD, Guevara-Patino, JA, Goldberg, SM, Houghton, AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002; 188: 122–35.
Newton, R, Ziegler, J, Ateenyi-Agaba, Cet al. The epidemiology of conjunctival squamous cell carcinoma in Uganda. Br J Cancer 2002; 87: 301–8.
Mbulaiteye, SM, Parkin, DM, Rabkin, CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am 2003; 17: 673–96, v.
Goedert, JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000; 27: 390–401.
Ishida, H, Matsumura, T, Salgaller, MLet al. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 1996; 69: 375–80.
Jager, E, Jager, D, Knuth, A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14: 178–82.
Reichert, TE, Day, R, Wagner, EM, Whiteside, TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998; 58: 5344–7.
Sarioglu, T, Yilmaz, T, Sungur, A, Gursel, B. The effect of lymphocytic infiltration on clinical survival in cancer of the tongue. Eur Arch Otorhinolaryngol 1994; 251: 366–9.
Grogg, KL, Lohse, CM, Pankratz, VS, Halling, KC, Smyrk, TC. Lymphocyte-rich gastric cancer: associations with Epstein–Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003; 16: 641–51.
Wang, HH, Wu, MS, Shun, CTet al. Lymphoepithelioma-like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein–Barr virus infection. Hepatogastroenterology 1999; 46: 1214–19.
Yin, XY, Lu, MD, Lai, YR, Liang, LJ, Huang, JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003 Sep–Oct; 50(53): 1281–4.
Jass, JR. Pathology of hereditary nonpolyposis colorectal cancer. Ann NY Acad Sci 2000; 910: 62–73; discussion 73–4.
Michael-Robinson, JM, Biemer-Huttmann, A, Purdie, DMet al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001; 48: 360–6.
Coca, S, Perez-Piqueras, J, Martinez, Det al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79: 2320–8.
Mori, M, Ohtani, H, Naito, Yet al. Infiltration of CD8+ T-cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med 2000; 191: 113–18.
Toomey, D, Smyth, G, Condron, Cet al. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. Int J Cancer 2003; 103: 408–12.
Eerola, AK, Soini, Y, Paakko, P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000; 6: 1875–81.
Villegas, FR, Coca, S, Villarrubia, VGet al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35: 23–8.
Takanami, I, Takeuchi, K, Giga, M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 2001; 121: 1058–63.
Eerola, AK, Soini, Y, Paakko, P. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. Lung Cancer 1999; 26: 73–83.
Zeid, NA, Muller, HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993; 25: 338–43.
Han, AJ, Xiong, M, Gu, YY, Lin, SX. Lymphoepithelioma-like carcinoma of the lung with a better prognosis. A clinicopathologic study of 32 cases. Am J Clin Pathol 2001; 115: 841–50.
Deligdisch, L, Jacobs, AJ, Cohen, CJ. Histologic correlates of virulence in ovarian adenocarcinoma. II. Morphologic correlates of host response. Am J Obstet Gynecol 1982; 144: 885–9.
Dundar, E, Tel, N, Ozalp, SSet al. The significance of local cellular immune response of women 50 years of age and younger with endometrial carcinoma. Eur J Gynaecol Oncol 2002; 23: 243–6.
Bethwaite, PB, Holloway, LJ, Thornton, A, Delahunt, B. Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study. Pathology 1996; 28: 321–7.
Husseinzadeh, N, Wesseler, T, Schellhas, H, Nahhas, W. Significance of lymphoplasmocytic infiltration around tumor cell in the prediction of regional lymph node metastases in patients with invasive squamous cell carcinoma of the vulva: a clinicopathologic study. Gynecol Oncol 1989; 34: 200–5.
Evensen, JF, Fossa, SD, Kjellevold, K, Lien, HH. Testicular seminoma: histological findings and their prognostic significance for stage II disease. J Surg Oncol 1987; 36: 166–9.
Kolbeck, PC, Kaveggia, FF, Johansson, SL, Grune, MT, Taylor, RJ. The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. Mod Pathol 1992; 5: 420–5.
Tomita, K, Okui, N, Kimura, Aet al. Prognostic significance of histopathological findings (including lymphocyte infiltration) in renal cell carcinoma. Hinyokika Kiyo 1996; 42: 925–30.
Lipponen, PK, Eskelinen, MJ, Jauhiainen, K, Harju, E, Terho, R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 1992; 29A: 69–75.
Nzula, S, Going, JJ, Stott, DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003; 63: 3275–80.
Lawry, J, Rogers, K, Duncan, JL, Potter, CW. The identification of informative parameters in the flow cytometric analysis of breast carcinoma. Eur J Cancer 1993; 29A: 719–23.
Lucin, K, Iternicka, Z, Jonjic, N. Prognostic significance of T-cell infiltrates, expression of beta 2-microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1994; 190: 1134–40.
Lowe, D, Jorizzo, J, Hutt, MS. Tumour-associated eosinophilia: a review. J Clin Pathol 1981; 34: 1343–8.
Menard, S, Fortis, S, Castiglioni, F, Agresti, R, Balsari, A. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61(Suppl 2): 67–72.
Tang, RP, Kacinski, B, Validire, Pet al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?J Cell Biochem 1990; 44: 189–98.
Rossi, ML, Jones, NR, Candy, Eet al. The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol (Berl) 1989; 78: 189–93.
Mork, SJ, Halvorsen, TB, Lindegaard, KF, Eide, GE. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986; 45: 65–78.
Brooks, WH, Markesbery, WR, Gupta, GD, Roszman, TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978; 4: 219–24.
Palma, L, Di Lorenzo, N, Guidetti, B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 1978; 49: 854–61.
Di Lorenzo, N, Palma, L, Nicole, S. Lymphocytic infiltration in long-survival glioblastomas: possible host's resistance. Acta Neurochir (Wien) 1977; 39: 27–33.
Vaquero, J, Coca, S, Oya, Set al. Presence and significance of NK cells in glioblastomas. J Neurosurg 1989; 70: 728–31.